Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

JOURNAL ARTICLE published December 2020 in JGH Open

Authors: Tetsu Tomonari | Yasushi Sato | Hironori Tanaka | Takahiro Tanaka | Tatsuya Taniguchi | Msasahiro Sogabe | Koichi Okamoto | Hiroshi Miyamoto | Naoki Muguruma | Tetsuji Takayama